Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 22, Issue 5, Pages 1293-1298Publisher
WILEY
DOI: 10.1111/ajt.17012
Keywords
basic (laboratory) research; science; bioengineering; graft survival; immunosuppressant; immunosuppression; immune modulation; organ perfusion and preservation; organ transplantation in general; solid organ transplantation; translational research; science
Categories
Funding
- United States National Institute of Health [NIBIB K08EB019495, NIDDK R01DK124420, NIH T32 HL007260, NHLBI R01HL140470]
Ask authors/readers for more resources
Patients undergoing organ transplantation have to deal with the lifelong commitment of immunosuppression after transitioning from organ dysfunction. The use of nanoparticles has emerged as a solution to the issues associated with long-term and systemic use of immunosuppressive agents in transplantation. This minireview describes the role of nanoparticles in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.
Patients undergoing organ transplantation transition from one life-altering issue (organ dysfunction) to a lifelong commitment-immunosuppression. Regimens of immunosuppressive agents (ISAs) come with significant side effects and comorbidities. Recently, the use of nanoparticles (NPs) as a solution to the problems associated with the long-term and systemic use of ISAs in transplantation has emerged. This minireview describes the role of NPs in organ transplantation and discusses obstacles to clinical implementation and pathways to clinical translation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
